ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2025
Impact of Continuous Glucose Monitoring for American Indian/Alaska Native Adults With Type 2 Diabetes Mellitus Not Using Insulin.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: American Indian and Alaskan Native (AI/AN) populations have the highest prevalence of type 2 diabetes mellitus (T2DM) in the United States. Continuous glucose monitors (CGMs) have revolutionized diabetes management, but their impact on AI/AN individuals with T2DM who are not insulin dependent remains understudied. Methods: A retrospective observational study was conducted using deidentified electronic health records from an outpatient Indian Health Service clinic between 2019 and 2024. Ninety-three AI/AN patients with non-insulin-dependent T2DM who used CGMs for ≥ 1 year were included. Hemoglobin A Results: The mean age of participants was 55 years and 60% were female. Mean (SD) HbA Conclusions: CGM use in an AI/AN population was significantly associated with improved glycemic control in patients with non- insulin-dependent T2DM. The effect was more pronounced in patients with higher baseline HbA
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.